An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis
Latest Information Update: 13 Jan 2022
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.